(2022). Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 17, 1455-1466. http://doi.org/10.2147/copd.s338436.
(2022). Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. Int J Chron Obstruct Pulmon Dis, 17, 415-426. http://doi.org/10.2147/copd.s336158.
(2022). Association between Inhaled β(2)-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. Int J Chron Obstruct Pulmon Dis, 17, 1205-1217. http://doi.org/10.2147/copd.s358927.
(2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133-141. http://doi.org/10.1080/15412555.2022.2045265.
(2022). Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. Copd, 19, 109-117. http://doi.org/10.1080/15412555.2022.2035705.